Condition

Relapsed or Refractory Multiple Myeloma (RRMM) clinical trials and research

• 7Clinical trials
• 32Countries

Newest Relapsed or Refractory Multiple Myeloma (RRMM) clinical trials

All recruiting trials (7)

• In Vivo PICX CAR-T Therapy for Relapsed or Refractory Multiple Myeloma

  A single-arm study is testing an in vivo CAR-T cell therapy (PICX Injection) to see if it is safe and can help people with relapsed or refractory multiple myeloma.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Kunming, Yunnan · NCT07715630

• F182112 versus standard care for relapsed or refractory multiple myeloma

  This study will test whether F182112 works better than standard treatments for adults whose multiple myeloma has come back or stopped responding after prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

  Recruiting Phase 3 Shandong New Time Pharmaceutical Co., LTD · Tianjing · NCT07579234

• Dual-target BCMA and GPRC5D CAR-T for relapsed/refractory multiple myeloma with extramedullary disease

  This will try a CAR-T cell treatment that targets both BCMA and GPRC5D for adults whose relapsed or refractory multiple myeloma has spread outside the bone marrow.

  Recruiting Phase 1 Beijing GoBroad Hospital · Shanghai · NCT07003568

• Dual-target BCMA–CD19 CAR-T therapy for relapsed or refractory multiple myeloma with extramedullary disease

  This trial will try a CAR-T treatment that targets both BCMA and CD19 for adults whose relapsed or refractory multiple myeloma has spread outside the bone marrow.

  Recruiting Phase 1 Beijing GoBroad Hospital · Shanghai · NCT07003555

• Using patients' own modified immune cells to treat certain blood cancers

  This study is testing a new treatment using modified immune cells to see if it can help people with certain blood cancers like multiple myeloma, leukemia, and lymphoma.

  Recruiting Anhui Provincial Hospital · Hefei · NCT06961669

• Comparing BMS-986393 with standard treatments for relapsed multiple myeloma

  This study is testing a new drug called BMS-986393 to see if it works better than standard treatments for adults with relapsed multiple myeloma who haven't responded to lenalidomide.

  Recruiting at 122 sites Phase 3 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Birmingham, Alabama and 140 other locations · NCT06615479

• Combining Purinostat Mesylate with Pomalidomide and Dexamethasone for Multiple Myeloma

  This study is testing if a new combination of medications can be safely used to help people with relapsed or hard-to-treat multiple myeloma.

  Recruiting Phase 1/2 Chengdu Zenitar Biomedical Technology Co., Ltd · Chengdu, Sichuan · NCT06484829

Related topics

Quick answers

How many Relapsed or Refractory Multiple Myeloma (RRMM) clinical trials are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 32 countries. The most sites are in China (6 trials), Argentina (1 trial), Australia (1 trial), Austria (1 trial), Belgium (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 3, Phase 3: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →